Results 81 to 90 of about 866,467 (316)
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens +8 more
wiley +1 more source
Native American Advisory Circle Members
List of Native American Advisory Circle Members from 2020 to ...
Texas Christian University. Native American Advisory Circle
core
Protein aggregates threaten proteostasis and cell health. In human cells, Hsp70–J‐domain protein‐based disaggregases remove aggregates, but how they assemble remains unclear. Our biochemical findings show that DNAJA2‐ and DNAJB1‐containing disaggregase scaffolds enhance luciferase aggregate targeting, and that Hsp70 recruitment by both J‐domain ...
Anna Szlachcic, Nadinath B. Nillegoda
wiley +1 more source
Uludağ’da Girland ve Çember Oluşumları
Alpine zone of the Uludağ is under the influence of periglacial processes and landforms. As a result of this processes, garlands and circles have appeared to be dominant landforms. Because of the general direction of the Uludağ massif, the summit portion
Murat Türkeş, Muhammed Zeynel Öztürk
doaj +1 more source
Free and classical entropy over the circle. [PDF]
Relative entropy with respect to normalized arclength measure on the circle is greater than or equal to the negative logarithmic energy (Voiculescu's negative free entropy) and is greater than or equal to the modified relative free entropy.
Blower, Gordon
core
The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce +11 more
wiley +1 more source
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source

